Akebia Therapeutics (AKBA) Revenue & Revenue Breakdown
Akebia Therapeutics Revenue Highlights
Latest Revenue (Y)
$194.62M
Latest Revenue (Q)
$32.61M
Main Segment (Y)
Product
Main Geography (Y)
Product
Akebia Therapeutics Revenue by Period
Akebia Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $194.62M | -33.49% |
| 2022-12-31 | $292.60M | 37.00% |
| 2021-12-31 | $213.58M | -27.68% |
| 2020-12-31 | $295.31M | -11.85% |
| 2019-12-31 | $335.00M | 61.26% |
| 2018-12-31 | $207.74M | 16.72% |
| 2017-12-31 | $177.98M | 11495.05% |
| 2016-12-31 | $1.53M | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2012-12-31 | - | - |
Akebia Therapeutics generated $194.62M in revenue during NA 2023, up -33.49% compared to the previous quarter, and up 93.68% compared to the same period a year ago.
Akebia Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $32.61M | -41.98% |
| 2023-12-31 | $56.20M | 33.65% |
| 2023-09-30 | $42.05M | -25.42% |
| 2023-06-30 | $56.38M | 40.49% |
| 2023-03-31 | $40.13M | -27.28% |
| 2022-12-31 | $55.18M | 12.70% |
| 2022-09-30 | $48.96M | -61.37% |
| 2022-06-30 | $126.76M | 105.45% |
| 2022-03-31 | $61.70M | 3.51% |
| 2021-12-31 | $59.60M | 22.25% |
| 2021-09-30 | $48.76M | -7.86% |
| 2021-06-30 | $52.91M | 1.16% |
| 2021-03-31 | $52.30M | -7.75% |
| 2020-12-31 | $56.70M | -5.48% |
| 2020-09-30 | $59.99M | -33.45% |
| 2020-06-30 | $90.14M | 1.88% |
| 2020-03-31 | $88.48M | 27.21% |
| 2019-12-31 | $69.56M | -24.38% |
| 2019-09-30 | $91.98M | -8.76% |
| 2019-06-30 | $100.80M | 38.72% |
| 2019-03-31 | $72.67M | 21.41% |
| 2018-12-31 | $59.85M | 12.57% |
| 2018-09-30 | $53.17M | 8.97% |
| 2018-06-30 | $48.79M | 6.23% |
| 2018-03-31 | $45.93M | -47.40% |
| 2017-12-31 | $87.32M | 111.51% |
| 2017-09-30 | $41.28M | 44.75% |
| 2017-06-30 | $28.52M | 36.69% |
| 2017-03-31 | $20.86M | 1259.28% |
| 2016-12-31 | $1.53M | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | - |
Akebia Therapeutics generated $32.61M in revenue during Q1 2024, up -41.98% compared to the previous quarter, and up 59.09% compared to the same period a year ago.
Akebia Therapeutics Revenue Breakdown
Akebia Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Product | $170.30M | $177.07M | $142.22M | $128.90M | $111.12M |
| License Collaboration And Other Revenue | $24.32M | $115.53M | $71.36M | $166.41M | $223.88M |
Akebia Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (87.50%), and License Collaboration And Other Revenue (12.50%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License Collaboration And Other Revenue | $1.60M | $4.89M | $14.13M | $5.30M | $5.50M | $6.72M | $83.06M | $20.25M | $17.51M | $12.00M | $19.95M | $21.90M | $22.09M | $25.60M | $59.45M | $59.27M | $40.64M | $10.00M | - | - |
| Product | $31.01M | $93.23M | $42.24M | $34.83M | $49.68M | $42.24M | $43.70M | $41.45M | $42.10M | $36.75M | $32.96M | $30.41M | $34.60M | $34.39M | $30.70M | $29.21M | $28.91M | $30.00M | $23.11M | - |
Akebia Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product (95.10%), and License Collaboration And Other Revenue (4.90%).
Akebia Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| Product | $177.07M | $142.22M | $128.90M | $111.12M | - |
| License Collaboration And Other Revenue | $115.53M | $71.36M | $166.41M | $223.88M | $200.47M |
Akebia Therapeutics's latest annual revenue breakdown by geography, as of Dec 22: Product (60.51%), and License Collaboration And Other Revenue (39.49%).
Quarterly Revenue by Country
| Country | Mar 23 | Jun 20 |
|---|---|---|
| License Collaboration And Other Revenue | $5.30M | - |
| Product | $34.83M | - |
| Non-US | - | $65.00M |
Akebia Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 23: Product (86.79%), and License Collaboration And Other Revenue (13.21%).
Akebia Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AKBA | Akebia Therapeutics | $194.62M | $32.61M |
| MCRB | Seres Therapeutics | $126.33M | - |
| CDTX | Cidara Therapeutics | $63.91M | $8.46M |
| CWBR | CohBar | - | - |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| AVRO | AVROBIO | - | - |
| ELEV | Elevation Oncology | - | - |
| OCEA | Ocean Biomedical | - | - |
| HEPA | Hepion Pharmaceuticals | - | - |
| ENVB | Enveric Biosciences | - | - |
AKBA Revenue FAQ
What is Akebia Therapeutics’s yearly revenue?
Akebia Therapeutics's yearly revenue for 2023 was $194.62M, representing a decrease of -33.49% compared to 2022. The company's yearly revenue for 2022 was $292.6M, representing an increase of 37.00% compared to 2021. AKBA's yearly revenue for 2021 was $213.58M, representing a decrease of -27.68% compared to 2020.
What is Akebia Therapeutics’s quarterly revenue?
Akebia Therapeutics's quarterly revenue for Q1 2024 was $32.61M, a -41.98% decrease from the previous quarter (Q4 2023), and a -18.74% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $56.2M, a 33.65% increase from the previous quarter (Q3 2023), and a 1.84% increase year-over-year (Q4 2022). AKBA's quarterly revenue for Q3 2023 was $42.05M, a -25.42% decrease from the previous quarter (Q2 2023), and a -14.13% decrease year-over-year (Q3 2022).
What is Akebia Therapeutics’s revenue growth rate?
Akebia Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -8.87%, and for the last 5 years (2019-2023) was -41.90%.
What are Akebia Therapeutics’s revenue streams?
Akebia Therapeutics's revenue streams in c 23 are Product, and License Collaboration And Other Revenue. Product generated $170.3M in revenue, accounting 87.50% of the company's total revenue, down -3.82% year-over-year. License Collaboration And Other Revenue generated $24.32M in revenue, accounting 12.50% of the company's total revenue, down -78.95% year-over-year.
What is Akebia Therapeutics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Akebia Therapeutics was Product. This segment made a revenue of $170.3M, representing 87.50% of the company's total revenue.